Darwin A. Garcia PhD , Jennifer M. Fazzari PhD , Ruslan Hlushchuk MD , Oleksiy-Zakhar Khoma MS , Katrina K. Bakken CVT , Danielle M. Burgenske PhD , Scott C. Lester MD , Robert W. Mutter MD , Fabrice Lucien PhD , Nicholas B. Remmes PhD , Jann N. Sarkaria MD , Sean S. Park MD, PhD , Valentin G. Djonov MD , Michael P. Grams PhD
{"title":"Minibeam Radiation Therapy Valley Dose Determines Tolerance to Acute and Late Effects in the Mouse Oral Cavity","authors":"Darwin A. Garcia PhD , Jennifer M. Fazzari PhD , Ruslan Hlushchuk MD , Oleksiy-Zakhar Khoma MS , Katrina K. Bakken CVT , Danielle M. Burgenske PhD , Scott C. Lester MD , Robert W. Mutter MD , Fabrice Lucien PhD , Nicholas B. Remmes PhD , Jann N. Sarkaria MD , Sean S. Park MD, PhD , Valentin G. Djonov MD , Michael P. Grams PhD","doi":"10.1016/j.ijrobp.2025.03.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Minibeam radiation therapy (MBRT) is an innovative strategy to improve normal tissue sparing by delivering alternating, submillimeter-wide regions of high “peak” and low “valley” doses. The purpose of this study was to characterize both acute and late MBRT-induced normal tissue toxicities and determine the dosimetric parameters that dictate toxicity.</div></div><div><h3>Methods and Materials</h3><div><span>Mice were stratified by weight and randomized to receive a single dose of conventional radiation therapy (uniform open field) or MBRT (0.5 mm-wide minibeams spaced 1.1 mm center to center) to the oral cavity. The conventional RT groups (n = 4 per group) received 16 or 20 Gy, whereas the MBRT groups (n = 5 per group) received peak:valley doses of 48:8, 72:12, 96:8, 96:16, or 152:8 Gy. </span>Acute toxicity<span> (≤3 weeks) was evaluated using changes in weight and mucosal histology. Late effects on bone and dentition were evaluated using microscopic computed tomography (microCT).</span></div></div><div><h3>Results</h3><div>Animals irradiated with 16 Gy (n = 1), 20 Gy (n = 4), and 96:16 Gy (n = 5) reached acute toxicity endpoint (≥20% weight loss) between 9 and 11 days postradiation and exhibited histologic changes indicative of mucositis<span>. No animals in the other MBRT groups reached acute toxicity endpoint. Although 96:8 Gy induced marked mucosal damage in peak regions, the spared tissue in the valley regions enabled restoration of mucosal integrity within 2 weeks post-MBRT. MicroCT of surviving mice 12 months postradiation revealed an alternating pattern of decreased bone volume consistent with the MBRT pattern. The upper incisors of most animals were shortened or completely missing. The mice receiving 16 Gy and 48:8 Gy exhibited the most and least dental damage, respectively.</span></div></div><div><h3>Conclusions</h3><div>This preliminary study emphasizes that normal tissue sparing by MBRT, as determined by the valley dose, significantly ameliorates dose-limiting toxicities and enables escalation to MBRT peak doses up to an order of magnitude greater than conventional RT doses.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 1","pages":"Pages 262-269"},"PeriodicalIF":6.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301625002457","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
Minibeam radiation therapy (MBRT) is an innovative strategy to improve normal tissue sparing by delivering alternating, submillimeter-wide regions of high “peak” and low “valley” doses. The purpose of this study was to characterize both acute and late MBRT-induced normal tissue toxicities and determine the dosimetric parameters that dictate toxicity.
Methods and Materials
Mice were stratified by weight and randomized to receive a single dose of conventional radiation therapy (uniform open field) or MBRT (0.5 mm-wide minibeams spaced 1.1 mm center to center) to the oral cavity. The conventional RT groups (n = 4 per group) received 16 or 20 Gy, whereas the MBRT groups (n = 5 per group) received peak:valley doses of 48:8, 72:12, 96:8, 96:16, or 152:8 Gy. Acute toxicity (≤3 weeks) was evaluated using changes in weight and mucosal histology. Late effects on bone and dentition were evaluated using microscopic computed tomography (microCT).
Results
Animals irradiated with 16 Gy (n = 1), 20 Gy (n = 4), and 96:16 Gy (n = 5) reached acute toxicity endpoint (≥20% weight loss) between 9 and 11 days postradiation and exhibited histologic changes indicative of mucositis. No animals in the other MBRT groups reached acute toxicity endpoint. Although 96:8 Gy induced marked mucosal damage in peak regions, the spared tissue in the valley regions enabled restoration of mucosal integrity within 2 weeks post-MBRT. MicroCT of surviving mice 12 months postradiation revealed an alternating pattern of decreased bone volume consistent with the MBRT pattern. The upper incisors of most animals were shortened or completely missing. The mice receiving 16 Gy and 48:8 Gy exhibited the most and least dental damage, respectively.
Conclusions
This preliminary study emphasizes that normal tissue sparing by MBRT, as determined by the valley dose, significantly ameliorates dose-limiting toxicities and enables escalation to MBRT peak doses up to an order of magnitude greater than conventional RT doses.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.